Results 291 to 300 of about 1,030,253 (321)
Some of the next articles are maybe not open access.
Iron chelators and iron toxicity
Alcohol, 2003Iron chelation may offer new approaches to the treatment and prevention of alcoholic liver disease. With chronic excess, either iron or alcohol alone may individually injure the liver and other organs. In combination, each exaggerates the adverse effects of the other.
openaire +3 more sources
Current Opinion in Hematology, 2014
This review provides an update on advances in the area of iron chelation therapy, including new indications and uses of currently available agents, and preliminary data on potential new agents in development.Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years.
openaire +3 more sources
This review provides an update on advances in the area of iron chelation therapy, including new indications and uses of currently available agents, and preliminary data on potential new agents in development.Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years.
openaire +3 more sources
Iron Chelation for Iron Overload in Thalassemia.
Metal ions in life sciences, 2019This chapter is devoted to the chelation treatment of transfusion-dependent thalassemia patients. After a brief overview on the pathophysiology of iron overload and on the methods to quantify it in different organs, the chelation therapy is discussed ...
G. Crisponi, V. Nurchi, J. Lachowicz
semanticscholar +1 more source
Effect of Chelation on Iron–Chromium Redox Flow Batteries
, 2020The iron–chromium (FeCr) redox flow battery (RFB) was among the first flow batteries to be investigated because of the low cost of the electrolyte and the 1.2 V cell potential.
Scott E. Waters +2 more
semanticscholar +1 more source
Chelation of iron within the erythrocytic Plasmodium falciparum parasite by iron chelators
Molecular and Biochemical Parasitology, 1999To examine the site of action of antimalarial iron chelators, iron ligands were added to control erythrocytes and to erythrocytes parasitized with Plasmodium falciparum, and the concentration of intracellular labile iron was monitored with the fluorescent probe, calcein.
B. F. Dickens +5 more
openaire +3 more sources
2002
Although iron chelation therapy with deferoxamine (DFO) has changed life expectancy in thalassemic patients, compliance with the rigorous requirements of long-term subcutaneous DFO infusions is unsatisfactory. This problem underlines the current efforts for developing alternative, orally effective chelators to improve compliance and treatment results ...
Chaim Hershko +3 more
openaire +3 more sources
Although iron chelation therapy with deferoxamine (DFO) has changed life expectancy in thalassemic patients, compliance with the rigorous requirements of long-term subcutaneous DFO infusions is unsatisfactory. This problem underlines the current efforts for developing alternative, orally effective chelators to improve compliance and treatment results ...
Chaim Hershko +3 more
openaire +3 more sources
Current Opinion in Hematology, 1995
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
Iron chelation therapy is essential to prevent death from cardiac toxicity in patients with thalassemia major or other severe refractory anemias who need regular blood transfusions. Iron chelating drugs also have potential for clinical use as antiproliferative agents in neoplastic diseases and to reduce free radical-induced tissue damage in rheumatoid ...
openaire +2 more sources
Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry, 2012The study of iron chelators as anti-tumor agents is still in its infancy. Iron is important for cellular proliferation and this is demonstrated by observations that iron-depletion results in cell cycle arrest and also apoptosis. In addition, many iron chelators are known to inhibit ribonucleotide reductase, the iron-containing enzyme that is the rate ...
Yu, Yu +6 more
openaire +4 more sources
Combined iron chelation therapy
Annals of the New York Academy of Sciences, 2010Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications. Despite the availability of three iron chelators, some patients fail to respond adequately to monotherapy with any of them. Combination therapy, consisting in the use of two
Galanello Renzo +5 more
openaire +3 more sources
Iron Chelation in Thalassemia Major
Clinical Therapeutics, 2015Iron chelation has improved survival and quality of life of patients with thalassemia major. there are currently 3 commercially available iron-chelating drugs with different pharmacokinetic and pharmacodynamic activity. The choice of adequate chelation treatment should be tailored to patient needs and based on up-to-date scientific evidence.A review of
BORGNA, Caterina, Marsella, M.
openaire +2 more sources